Northern Trust Corp Monopar Therapeutics Transaction History

Northern Trust Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.39 - $3.73 $1,348 - $3,618	970 Added 2.69%	37,051 $51,000
Q4 2022 Feb 13, 2023	SELL	$2.05 - $14.95 $600 - $4,380	-293 Reduced 0.81%	36,081 $85,000
Q3 2022 Nov 14, 2022	BUY	$1.46 - $7.6 $1,709 - $8,899	1,171 Added 3.33%	36,374 $55,000
Q2 2022 Aug 12, 2022	SELL	$1.85 - $2.72 $7 - $10	-4 Reduced 0.01%	35,203 $81,000
Q1 2022 May 13, 2022	SELL	$2.5 - $3.62 $1,782 - $2,581	-713 Reduced 1.98%	35,207 $90,000
Q4 2021 Feb 08, 2022	SELL	$3.17 - $5.24 $1,328 - $2,195	-419 Reduced 1.15%	35,920 $115,000
Q3 2021 Nov 15, 2021	BUY	$4.5 - $6.0 $1,048 - $1,398	233 Added 0.65%	36,339 $177,000
Q2 2021 Aug 13, 2021	BUY	$5.05 - $6.49 $530 - $681	105 Added 0.29%	36,106 $213,000
Q1 2021 May 12, 2021	SELL	$5.76 - $10.6 $131,281 - $241,595	-22,792 Reduced 38.77%	36,001 $223,000
Q4 2020 Feb 11, 2021	SELL	$4.36 - $7.49 $25,963 - $44,602	-5,955 Reduced 9.2%	58,793 $360,000
Q3 2020 Nov 16, 2020	BUY	$4.93 - $8.15 $73,925 - $122,209	14,995 Added 30.14%	64,748 $347,000
Q2 2020 Aug 14, 2020	BUY	$6.4 - $9.5 $318,419 - $472,653	49,753 New	49,753 $372,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.